Showing results (491-500 of 502) with videos related to
Sort By:
Pageof 51
Epilepsy & Behavior : E&B|August 21, 2015
The relevance of neuropsychiatric symptoms and cognitive problems in new-onset epilepsy - Current knowledge and understandingB Pohlmann-Eden, A Aldenkamp, G A Baker, et al.Clinical Immunology (Orlando, Fla.)|January 13, 1999
Ex vivo assessment of immunosuppression in undiluted whole blood from pigs dosed with tacrolimus (FK506)Y W Chen, M L Smith, M P Sheets, et al.The Journal of Biological Chemistry|October 11, 2001
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compoundsJ M Trevillyan, X G Chiou, Y W Chen, et al.Cell Death and Differentiation|January 6, 2007
Bcl-2 family proteins are essential for platelet survivalH Zhang, P M Nimmer, S K Tahir, et al.The Journal of Investigative Dermatology|May 8, 1999
A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseasesK W Mollison, T A Fey, D M Gauvin, et al.Archives of Biochemistry and Biophysics|March 24, 1999
Inhibition of p56(lck) tyrosine kinase by isothiazolonesJ M Trevillyan, X G Chiou, S J Ballaron, et al.Proceedings of the National Academy of Sciences of the United States of America|December 5, 2008
Canopy nitrogen, carbon assimilation, and albedo in temperate and boreal forests: Functional relations and potential climate feedbacksS V Ollinger, A D Richardson, M E Martin, et al.Oncology (Williston Park, N.Y.)|February 24, 2001
NCCN Practice Guidelines for Breast CancerR W Carlson, B O Anderson, W Bensinger, et al.Current Pharmaceutical Design|April 10, 1999
Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseasesK W Mollison, T A Fey, D M Gauvin, et al.British Journal of Cancer|August 14, 2014
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100B P Schneider, L Li, F Shen, et al.Pageof 51